RAGE and Experimental Diabetic Neuropathy

Background: Heightened expression of the receptor for advanced glycation end products (RAGE) contributes to development of systemic diabetic complications, but its contribution to diabetic neuropathy is uncertain. Objective: We studied experimental diabetic neuropathy and its relationship with RAGE expression using streptozotocin (STZ) diabetic mice including a RAGE cohort exposed to long-term diabetes, as compared to littermates without diabetes. Methods: Structural indices of neuropathy were addressed with serial (1, 3, 5 and 9 months of experimental diabetes) electrophysiological and quantitative morphometric analysis of dorsal root ganglia (DRG), peripheral nerve and epidermal innervation. RAGE protein and mRNA levels in DRG, peripheral nerve, and epidermal terminals were assessed in wildtype and RAGE mice, with and without diabetes. The correlation of RAGE activation with nuclear factor κB (NFκB) and protein kinase C βII (PKCβII) protein and mRNA expression was also determined. Results: Diabetic peripheral epidermal axons, sural axons, Schwann cells and sensory neurons within ganglia developed dramatic and cumulative rises in RAGE mRNA and protein along with progressive electrophysiological and structural abnormalities. RAGE /mice had attenuated structural features of neuropathy after 5 months of diabetes. RAGE-mediated signaling pathway activation for NFκB and PKCβII pathways was most evident amongst Schwann cells in the DRG and peripheral nerve. Conclusion: In a long-term model of experimental diabetes resembling human diabetic peripheral neuropathy, RAGE expression in the peripheral nervous system rises cumulatively, and relates to progressive pathological changes. Mice lacking RAGE have attenuated features of neuropathy and limited activation of potentially detrimental signaling pathways.

[1]  P. Low,et al.  Enhanced inflammatory response via activation of NF-κB in acute experimental diabetic neuropathy subjected to ischemia–reperfusion injury , 2006, Journal of the Neurological Sciences.

[2]  S. Chung,et al.  Aldose Reductase–Deficient Mice Are Protected From Delayed Motor Nerve Conduction Velocity, Increased c-Jun NH2-Terminal Kinase Activation, Depletion of Reduced Glutathione, Increased Superoxide Accumulation, and DNA Damage , 2006, Diabetes.

[3]  D. Zochodne,et al.  Remote neurotrophic support of epidermal nerve fibres in experimental diabetes , 2006, Diabetologia.

[4]  R. Pop-Busui,et al.  Peripheral nerve dysfunction in experimental diabetes is mediated by cyclooxygenase-2 and oxidative stress. , 2005, Antioxidants & redox signaling.

[5]  E. Schleicher,et al.  The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). , 2005, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[6]  J. Groves,et al.  Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  D. Zochodne,et al.  Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage? , 2005, Diabetes.

[8]  J. Schapansky,et al.  Activation of nuclear factor-kappaB via endogenous tumor necrosis factor alpha regulates survival of axotomized adult sensory neurons. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[9]  J. Schneider,et al.  Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. , 2004, The Journal of clinical investigation.

[10]  C. Yabe-Nishimura,et al.  Neurotrophin‐3‐induced production of nerve growth factor is suppressed in Schwann cells exposed to high glucose: involvement of the polyol pathway , 2004, Journal of neurochemistry.

[11]  Ling-Hao Li,et al.  Advanced glycation end products potentiate the stimulatory effect of glucose on macrophage lipoprotein lipase expression Published, JLR Papers in Press, June 21, 2004. DOI 10.1194/jlr.M400169-JLR200 , 2004, Journal of Lipid Research.

[12]  R. Ramasamy,et al.  RAGE Axis: Animal Models and Novel Insights Into the Vascular Complications of Diabetes , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[13]  S. Yagihashi,et al.  Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells. , 2004, Biochemical and biophysical research communications.

[14]  C. Cheng,et al.  Diabetes Mellitus and the Sensory Neuron , 2004, Journal of neuropathology and experimental neurology.

[15]  S. Yagihashi,et al.  Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice , 2003, Journal of neurochemistry.

[16]  S. Chung,et al.  Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress , 2003, Molecular and Cellular Neuroscience.

[17]  V. D’Agati,et al.  RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.

[18]  A. Vinik,et al.  Prevention of the complications of diabetes. , 2003, The American journal of managed care.

[19]  B. Carter,et al.  Activation of the transcription factor NF-κB in Schwann cells is required for peripheral myelin formation , 2003, Nature Neuroscience.

[20]  H. Huttunen,et al.  Receptor for Advanced Glycation End Products (RAGE) Signaling Induces CREB-dependent Chromogranin Expression during Neuronal Differentiation* , 2002, The Journal of Biological Chemistry.

[21]  M. Cotter,et al.  Effects of protein kinase Cβ inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism , 2002, Diabetes/metabolism research and reviews.

[22]  J. Mamputu,et al.  Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide. , 2002, Journal of diabetes and its complications.

[23]  H. Brismar,et al.  Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. , 2002, Kidney international.

[24]  C. Lacroix,et al.  Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients , 2002, Journal of Neurology.

[25]  J. Wautier,et al.  AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. , 2002, Kidney international.

[26]  S. Tripp,et al.  Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy , 2001, Neurology.

[27]  C. Cheng,et al.  Does diabetes target ganglion neurones? Progressive sensory neurone involvement in long-term experimental diabetes. , 2001, Brain : a journal of neurology.

[28]  J. Wautier,et al.  Advanced glycation end products, their receptors and diabetic angiopathy. , 2001, Diabetes & metabolism.

[29]  A. Heidland,et al.  Advanced glycation end products and the progressive course of renal disease. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  M. Mattson,et al.  Endoplasmic Reticulum d-myo-Inositol 1,4,5-Trisphosphate-sensitive Stores Regulate Nuclear Factor-κB Binding Activity in a Calcium-independent Manner* , 2001, The Journal of Biological Chemistry.

[31]  A. Schmidt,et al.  Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.

[32]  G. Jerums,et al.  Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. , 2001, Clinical science.

[33]  H. Huttunen,et al.  Coregulation of Neurite Outgrowth and Cell Survival by Amphoterin and S100 Proteins through Receptor for Advanced Glycation End Products (RAGE) Activation* , 2000, The Journal of Biological Chemistry.

[34]  G. Moretto,et al.  Tumor Necrosis Factor α and Human Schwann Cells: Signalling and Phenotype Modulation Without Cell Death , 2000, Journal of neuropathology and experimental neurology.

[35]  R. Kikkawa,et al.  Evaluation of diabetic neuropathy through the quantitation of cutaneous nerves , 2000, Journal of the Neurological Sciences.

[36]  H. Sano,et al.  Advanced glycation end product-induced peroxisome proliferator-activated receptor gamma gene expression in the cultured mesangial cells. , 1999, Biochemical and biophysical research communications.

[37]  N. Hotta,et al.  A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. , 1999, Diabetes.

[38]  A. Schmidt,et al.  Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.

[39]  J. Wautier,et al.  [Pathophysiologic aspects of diabetic angiopathy]. , 1999, Diabetes & metabolism.

[40]  P. Guillausseau,et al.  Diabetes, advanced glycation endproducts and vascular disease , 1998, Vascular medicine.

[41]  A. Schmidt,et al.  Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.

[42]  A. Schmidt,et al.  Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products* , 1997, The Journal of Biological Chemistry.

[43]  P. Guillausseau,et al.  Rapid Publication , 1971, Nature.

[44]  John G Flanagan,et al.  Complementary gradients in expression and binding of ELF-1 and Mek4 in development of the topographic retinotectal projection map , 1995, Cell.

[45]  G. Otto,et al.  Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. , 1995, The American journal of pathology.

[46]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.

[47]  Y. Zou,et al.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.

[48]  D. Zochodne,et al.  Normal blood flow but lower oxygen tension in diabetes of young rats: microenvironment and the influence of sympathectomy. , 1992, Canadian journal of physiology and pharmacology.

[49]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[50]  M. Bitensky,et al.  Structural and functional consequences of increased tubulin glycosylation in diabetes mellitus. , 1982, Proceedings of the National Academy of Sciences of the United States of America.